Upregulation of angiotensin II-AT1 receptors during statin withdrawal in vascular smooth muscle cells

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 6, 2007, Pages 708-711

  Castejon, Ana M ^a   Zollner, Emily ^a   Tristano, Antonio G ^a   Cubeddu, Luigi X ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Angiotensin II; AT1 receptors; Mitogen activated protein kinases; Statin withdrawal; Statins; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SIMVASTATIN; STATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; HEART DISEASE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIMVASTATIN; TIME FACTORS; UP-REGULATION;

EID: 37349039000     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318157c0b2     Document Type: Article

References (31)

1. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079-1082.
2. Stein EA. The power of statins: aggressive lipid lowering. Clin Cardiol. 2003;26:III25-III31.
3. Kinlay S, Schwartz GG, Olsson AG, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386-391.
4. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725-31729.
5. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-2719.
6. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Nat Acad Sci USA. 1998;95:8880-8885.
7. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
8. Chung HK, Lee IK, Kang H, et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med. 2002;34:451-461.
9. Seljeflot I, Tonstad S, Hjermann I, et al. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res. 2002;105:285-290.
10. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(Suppl 1):III39-III143.
11. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet. 1998;352:1830-1831.
12. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-1452.
13. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins in patients with acute coronary syndromes. Circulation. 2003;107: e27.
14. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med. 2004;164:2162-2168.
15. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004;140:857-866.
16. Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy. 2006;26:1288-1296.
17. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102:3104-3110.
18. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res. 2002;91:173-179.
19. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke. 2004;35:2708-2711.
20. Brandes RP, Beer S, Ha T, et al. Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:1794-1800.
21. Tristano AG, Castejon AM, Castro A, et al. Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 2007;353:11-17.
22. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639-672.
23. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptor. Ann Rev Physiol. 1997;59:395-412.
24. Battle T, Arnal JF, Challah M, et al. Selective isolation of rat aortic wall layers and their cell types in culture-application to converting enzyme activity measurement. Tissue Cell. 1994;26:943-955.
25. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension. 1998;31:152-161.
26. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol. 2007;292:C82-C97.
27. Liao DF, Duff JL, Daum G, et al. Angiotensin II stimulates MAP kinase kinase kinase activity in vascular smooth muscle cells, Role of Raf. Circ Res. 1996;79:1007-1014.
28. Touyz RM, Yao G. Up-regulation of vascular and renal mitogen-activated protein kinases in hypertensive rats is normalized by inhibitors of the Na+/Mg2+ exchanger. Clin Sci (Lond). 2003;105:235-242.
29. Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:1896-1901.
30. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-654.
31. Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl. 2006;24:S15-21.